| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Zelinka1,5
í Widimsk
, Jr5
1 Reproductive Biology and Medicine Branch, National Institutes of Child Health and Human Development2 Nuclear Medicine Department, 3 Department of Diagnostic Radiology and 4 Clinical Neurocardiology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, USA5 3rd Department of Medicine, 1st Faculty of Medicine, General Faculty Hospital, U Nemocnice 1, Prague 2, 128 08, Czech Republic6 Department of Medicine, P. J. 
afaík University, SNP 1, Koice, 041 66, Slovak Republic
(Correspondence should be addressed to K Pacak who is now at Section on Medical Neuroendocrinology, Reproductive Biology and Medicine Branch, National Institutes of Child Health and Human Development, 10 Center Drive, Building 10, CRC, RM 1-E 3140, MSC 1109, Bethesda, Maryland 20892-1109, USA; Email: karel{at}mail.nih.gov)
We performed a retrospective analysis of 71 subjects with metastatic pheochromocytoma and paraganglioma (30 subjects with mutation of succinate dehydrogenase enzyme subunit B (SDHB) gene and 41 subjects without SDHB mutation). Sixty-nine percent presented with bone metastases (SDHB +/–: 77% vs 63%), 39% with liver metastases (SDHB +/–: 27% vs 47%), and 32% with lung metastases (SDHB +/–: 37% vs 29%). The most common sites of bone involvement were thoracic spine (80%; SDHB+/–: 83% vs 77%), lumbar spine (78%; SDHB +/–: 78% vs 75%), and pelvic and sacral bones (78%; SDHB +/–: 91% vs 65%, P=0.04). Subjects with SDHB mutation also showed significantly higher involvement of long bones (SDHB +/–: 78% vs 30%, P=0.007) than those without the mutation. The best overall sensitivity in detecting bone metastases demonstrated positron emission tomography (PET) with 6-[18F]-fluorodopamine ([18F]-FDA; 90%), followed by bone scintigraphy (82%), computed tomography or magnetic resonance imaging (CT/MRI; 78%), 2-[18F]-fluoro-2-deoxy-D-glucose ([18F]-FDG) PET (76%), and scintigraphy with [123/131I]-metaiodobenzylguanidine (71%). In subjects with SDHB mutation, imaging modalities with best sensitivities for detecting bone metastases were CT/MRI (96%), bone scintigraphy (95%), and [18F]-FDG PET (92%). In subjects without SDHB mutations, the modality with the best sensitivity for bone metastases was [18F]-FDA PET (100%). In conclusion, bone scintigraphy should be used in the staging of patients with malignant pheochromocytoma and paraganglioma, particularly in patients with SDHB mutations. As for PET imaging, [18F]-FDG PET is highly recommended in SDHB mutation patients, whereas [18F]-FDA PET is recommended in patients without the mutation.
This article has been cited by other articles:
|
|
 |
|
  H.-B. Fiebrich, A. H. Brouwers, M. N. Kerstens, M. E. J. Pijl, I. P. Kema, J. R. de Jong, P. L. Jager, P. H. Elsinga, R. A. J. O. Dierckx, J. E. van der Wal, et al. 6-[F-18]Fluoro-L-Dihydroxyphenylalanine Positron Emission Tomography Is Superior to Conventional Imaging with 123I-Metaiodobenzylguanidine Scintigraphy, Computer Tomography, and Magnetic Resonance Imaging in Localizing Tumors Causing Catecholamine Excess J. Clin. Endocrinol. Metab., October 1, 2009; 94(10): 3922 - 3930. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Taieb, F. Sebag, A. Barlier, L. Tessonnier, F. F. Palazzo, I. Morange, P. Niccoli-Sire, N. Fakhry, C. De Micco, S. Cammilleri, et al. 18F-FDG Avidity of Pheochromocytomas and Paragangliomas: A New Molecular Imaging Signature? J. Nucl. Med., May 1, 2009; 50(5): 711 - 717. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
